Herpes zoster vaccine（recombinant，adjuvanted）

Vaccination with recombinant zoster vaccine (RZV) reduces herpes zoster (HZ) risk in individuals with inflammatory bowel disease (IBD), with a lower incidence observed in vaccinated IBD patients compared to unvaccinated controls. The vaccine is cost-effective and recommended for IBD patients aged 19 and older.

A study compared the recombinant zoster vaccine (RZV) with the zoster vaccine live (ZVL) for efficacy and safety, finding RZV more effective with 90% efficacy against shingles. Despite rare adverse events like dermatomal reactions, RZV remains the preferred vaccine for varicella zoster virus (VZV) prevention, necessitating further monitoring and studies on its immunomodulatory effects.

GSK's phase 3 trial shows non-inferior immune responses, reactogenicity, and safety when co-administering Arexvy (RSV vaccine) and Shingrix (shingles vaccine) in adults 50+ compared to separate administration, aiming to simplify vaccination regimens.

GSK launches Shingrix (RZV) in Malaysia for shingles prevention in adults 50+ and 18+ at risk, targeting VZV reactivation and PHN.